Novel bispecific antibody allows weekly prophylaxis for haemophilia A

Once weekly prophylaxis with emicizumab leads to a significantly lower bleeding rate in people with severe haemophilia A without factor VIII inhibitors compared to no prophylaxis or previous treatment with factor VIII prophylaxis, a phase 3 trial has shown. A study of 152 patients from age 12 years extends an earlier efficacy and safety study ...

Already a member?

Login to keep reading.

© 2021 the limbic